In kidney disease, lower blood pressure still protects the heart

Doctors have long hesitated to push blood pressure hard in patients whose kidneys are already failing, worried that aggressive treatment might starve the kidneys of pressure and hasten their decline. A large new synthesis of the trial evidence pushes back on that caution: lowering blood pressure protects the heart roughly as much in people with chronic kidney disease as in those without, and the main downside appears to be a change in kidney numbers rather than in kidney failure itself [s1].

Chronic kidney disease and high blood pressure feed each other. Damaged kidneys drive pressure up, and high pressure damages kidneys further, which is why people with kidney disease are far more likely to die of a heart attack or stroke than to reach dialysis. The open question has been how low to aim, because the kidneys sit downstream of blood pressure in a way the heart does not [s1].

What the study did

Researchers pooled 27 randomised trials — reported across 41 publications — that compared more intensive blood-pressure lowering against a standard target, searching the medical literature through 16 January 2026 [s1]. Together the trials enrolled 88,830 participants. For the analysis of cardiovascular events, 11,103 had chronic kidney disease and 76,785 did not [s1]. Rather than compare fixed targets, the authors expressed the benefit per 10-mmHg reduction in systolic pressure, a standard way to put trials with different goals on one scale [s1]. The work was funded by a European Renal Association fellowship with no industry support [s1].

What it found

Across all participants, each 10-mmHg reduction in systolic pressure cut the risk of a major cardiovascular event by about 15% — a relative risk of 0.85 (95% confidence interval 0.81 to 0.89) [s1]. Splitting by kidney status, the effect held in both groups: a relative risk of 0.89 (0.81 to 0.99) in people with chronic kidney disease and 0.84 (0.80 to 0.88) in those without, with no statistically significant difference between them (interaction P=.26) [s1]. In absolute terms the benefit was, if anything, slightly larger where kidneys were impaired — about 4.3 fewer major events per 1,000 person-years in the kidney-disease group versus 2.7 in those without — because those patients start at higher risk [s1]. All-cause mortality also fell, with a relative risk of 0.89 (0.83 to 0.95) [s1].

The kidney findings are where the nuance lives. The risk of kidney failure itself was essentially unchanged — a relative risk of 0.97 (0.84 to 1.11), again with no difference by baseline kidney status [s1]. But intensive lowering was associated with more frequent drops in estimated filtration rate: a relative risk of 1.42 (1.28 to 1.58) for a decline of 30% or more, and 1.47 (1.30 to 1.66) for a decline of 40% or more [s1]. That pattern — a worse surrogate number without a worse hard outcome — fits a long-recognised quirk of these drugs: an acute, often reversible dip in filtration when pressure is brought down, which can look alarming on a lab report without signalling true kidney injury [s1].

How to read it

The practical message is that a diagnosis of chronic kidney disease is not, by itself, a reason to settle for looser blood-pressure control [s1]. The heart-and-survival benefit of lowering pressure carried over to the kidney-disease group, and because those patients are at higher baseline risk, the absolute payoff was at least as large [s1]. The counterweight is that clinicians should expect filtration numbers to wobble downward when they intensify treatment, and the evidence here suggests that dip tracks the pressure change rather than a march toward dialysis [s1].

The limits are worth stating. This is a meta-analysis of tabulated trial results, not of individual patient records, so it cannot fully untangle who benefits most, and the trials measured blood pressure in different ways [s1]. The eGFR-decline signal also deserves follow-up, since not every dip is benign. For related coverage, see how SGLT2 inhibitors protect the kidneys and heart beyond diabetes, what cutting salt does in kidney disease, and the two conditions that do most to protect your kidneys.

What to watch

Guideline committees will weigh whether to drop the softer targets still written into some kidney protocols, and whether the short-term filtration dip needs a monitoring rule attached [s1]. The larger lesson is an old one made sharper: in kidney disease the heart is usually the thing that kills, and treating blood pressure is treating the heart.

This article describes research and is not medical advice. Blood-pressure targets are a decision for treating clinicians.

Sources

• Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease — JAMA Cardiology, 7 October 2026